AlgoRx Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Secaucus NJ United States (2001)
Status: Acquired by Anesiva, Inc. (2005)

Organization Overview

First Clinical Trial
2004
NCT00132405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

lidocaine (xylocaine) (3 trials)

Drugs in Phase 2 Trials (1)

capsaicin (qutenza) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hernia (Phase 2)

Knee Injuries (Phase 2)

Morton Neuroma (Phase 2)

Neuroma (Phase 2)

Pain, Postoperative (Phase 2)

Pain, Procedural (Phase 3)

Tennis Elbow (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 2